8-KShareholder MattersCorporate ChangesExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Bylaw Amendment (May 12, 2014)

Filed May 12, 2014For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on May 12, 2014, detailing events that occurred on May 6, 2014. The primary focus of this filing pertains to the company's Annual Meeting of Stockholders and amendments to its corporate governance documents. Key among these are the election of directors and the ratification of the independent auditor. Furthermore, the company's Board of Directors amended the Bylaws to formalize the role and duties of a Lead Independent Director, granting the Board discretion in appointing this position and outlining its responsibilities. The filing also provides detailed voting results for various proposals, including the advisory vote on executive compensation and a stockholder proposal regarding simple majority vote. Investors can glean insights into shareholder confidence in the board, auditor independence, and management's compensation practices.

Key Highlights

  • 1BMY held its Annual Meeting of Stockholders on May 6, 2014.
  • 2All 11 director nominees were elected by stockholders, indicating strong board support.
  • 3Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2014.
  • 4The advisory vote to approve the compensation of named executive officers was approved by stockholders.
  • 5The company amended its Bylaws to formalize the role and responsibilities of a Lead Independent Director.
  • 6The Board of Directors now has the discretion to appoint a Lead Independent Director.
  • 7A stockholder proposal for a simple majority vote received a significant number of 'For' votes, though it did not pass with the highest percentage.
  • 8The company reported substantial 'Non-Vote' figures across several director elections and proposals, likely due to broker non-votes.

Frequently Asked Questions

The main purpose of this 8-K filing was to report on the outcomes of Bristol-Myers Squibb's Annual Meeting of Stockholders held on May 6, 2014, and to announce amendments made to the company's Bylaws regarding the role of a Lead Independent Director.

Stockholders overwhelmingly approved the election of all 11 director nominees, with 'For' votes significantly outnumbering 'Against' and 'Abstain' votes for each nominee. This indicates strong shareholder confidence in the current board.

The Bylaws were amended to add a new section formalizing the role of a Lead Independent Director. This amendment clarifies that the Board of Directors may, at its discretion, appoint a Lead Independent Director and outlines the powers and duties associated with this position.

The advisory vote to approve the compensation of Bristol-Myers Squibb's named executive officers was approved by stockholders. The 'For' votes significantly exceeded the 'Against' and 'Abstain' votes.